Developing an Oncology Workforce for the 21st Century

项目摘要/摘要 芝加哥大学保罗·卡拉布雷西临床双轨职业发展奖的总体目标 肿瘤学的目标是增加高技能临床医生的数量(医学博士、医生、S、药学博士、拥有博士或博士学位的护士或 同等)和非临床医生博士后研究人员，能够设计和测试创新的 临床试验环境中以假设为导向的临床治疗研究方案(试点/第一阶段、第二阶段和 第三阶段试验)。为了做到这一点，我们在一个 学术上严格的培训环境，为最有吸引力的高级研究员或初级教员做准备 临床肿瘤学：以病人为中心的研究。该计划植根于我们的综合 癌症中心，由医学博士Olufunmilayo Olopade和医学博士Walter Stadler领导，并得到 执行委员会以及内部和外部咨询委员会。七十八年的科研培训 教员有NIH或同等同行评审的资金，在许多协作项目上互动 研究和培训工作，并完全有资格担任每年五名受训人员的潜在导师 参加这个K12项目。每名实习生的任期至少为两年。在这次更新中 应用，我们将继续该计划的成功元素在临床药理学，基因组学和 免疫疗法，同时增加临床信息学、数据科学等新兴领域的培训机会 和微生物组研究。保罗·卡拉布雷西K12奖学金计划是我们高度指导、讲授的 课程密集的课程，以及临床研究培训，最终获得理科硕士学位 临床调查。利用芝加哥医科大学的临床研究基础设施，我们 还创建了一套灵活的跨学科翻译科学综合课程，将 创业、癌症基因组学、免疫学、药物基因组学和社区临床试验 网络。自2010年以来完成该项目的18名学员中，有13名(72%)目前处于学术阶段 职业，其中7人(54%)担任副教授级别的职务。此外，这18名学员 发表肿瘤学研究论文共176篇，现为首席调查员或副调查员 56项肿瘤学研究资助奖。重要的是，在过去的14年中，有7次(50%)对该计划进行了任命 在筹资周期中，妇女或服务不足的少数群体的成员。这是保罗的一个明确目标 卡拉布雷西学者计划，与我们机构的所有培训计划一样，是它的培训机会 而福利将远远超出它将提供津贴的相对较少的学者。该计划 已经产生了革命性和全球性的影响，并正在进入更大的肿瘤学实习生社区 芝加哥和其他国家的受训人员作为全球肿瘤学学者来到我们机构。因此， 从该计划的实施和生产力中获得的好处是巨大的，并将 增加开展癌症临床试验的高技能临床医生和非临床医生数量。

PROJECT SUMMARY/ABSTRACT The overall goal of the dual-track University of Chicago Paul Calabresi Career Development Award for Clinical Oncology is to increase the number of highly skilled clinicians (M.D.s, D.O,s, Pharm.D., nurses with PhD or equivalent) and non-clinician postdoctoral researchers who are capable of designing and testing innovative hypothesis-driven clinical therapeutic research protocols in clinical trial settings (pilot/Phase I, Phase II and Phase III trials). To do this, we have created a tightly structured and mentored education program within an academically rigorous training environment that prepares the most compelling senior fellows or junior faculty in clinical oncology for careers in patient oriented research. The program is anchored within our Comprehensive Cancer Center and led by Olufunmilayo Olopade, MD along with Walter Stadler, MD with strong support from an Executive Committee as well as Internal and External Advisory Committees. The 78 research training faculty preceptors have NIH or equivalent peer- reviewed funding, interact on a number of collaborative research and training efforts and are well qualified to serve as potential mentors for the five trainees per year participating in this K12 program. Each trainee is appointed for a minimum of two years. In this renewal application, we shall continue successful elements of the program in clinical pharmacology, genomics and immunotherapy while enhancing training opportunities in emerging fields of clinical informatics, data science and microbiome research. The Paul Calabresi K12 Scholars Program is our highly mentored, didactic coursework-intensive program, and “hands on” clinical research training which results in a Master of Science in Clinical Investigation. Leveraging clinical research infrastructure across University of Chicago Medicine, we have also created a flexible set of integrated interdisciplinary courses in translational science that blends entrepreneurships, cancer genomics, immunology, pharmacogenomics and community based clinical trials network. Of the 18 trainees who have completed the program since 2010, 13 (72%) are currently in academic careers, of whom 7 (54%) hold appointments at the Associate Professor level. Moreover, these 18 trainees have published a total of 176 oncology research papers, and are Principal Investigators or Co-Investigators on 56 oncology research grant awards. Of significance, 7 of 14 (50%) appointments to the program in the last funding cycle were women or members of underserved minority groups. An explicit goal of this Paul Calabresi Scholars program, as with all training programs in our institution, is that its training opportunities and benefits will extend far beyond the relatively few scholars whose stipends it will provide. The program has had a transformative and global impact and is reaching into the larger oncology trainee community in Chicago and to trainees in other countries who come to our Institution as Global Oncology Scholars. Thus, the benefit that accrues from the program's implementation and productivity is substantial and will increase the number of highly skilled clinicians and non-clinicians conducting cancer clinical trials.